Factors | No. of patients | Median survival time (months) | 6-month survival (%) | 1-year survival (%) | 2-year survival (%) | p-value |
---|---|---|---|---|---|---|
All patients | 30 | 8.8 | 77 | 33 | 26 | Â |
Age | ||||||
  < 65 | 14 | 8.1 | 79 | 29 | 14 |  |
  ≥ 65 | 16 | 9.2 | 75 | 38 | 38 | 0.2 |
Gender | ||||||
  Male | 16 | 8.1 | 75 | 31 | 25 |  |
  Female | 14 | 9.2 | 79 | 36 | 29 | 0.6 |
Karnofsky performance status | ||||||
  ≥ 80 | 28 | 9.1 | 79 | 36 | 28 |  |
  < 80 | 2 | 4.8 | 50 | 0 | 0 | 0.03 |
Primary tumor location | ||||||
  Head | 15 | 9.4 | 93 | 40 | 33 |  |
  Body / tail | 15 | 8.5 | 60 | 27 | 18 | 0.5 |
Number of regimens of primary chemotherapy | ||||||
  1 | 25 | 9.4 | 80 | 40 | 32 |  |
  2 | 5 | 6.1 | 60 | 0 | 0 | 0.006 |
Best response to primary chemotherapy | ||||||
  PR | 9 | 9.2 | 89 | 33 | 33 |  |
  SD or PD | 21 | 8.5 | 71 | 33 | 24 | 0.6 |
Pre-chemoradiotherapy tumor diameter (cm) | ||||||
  ≤ 4 | 12 | 10.8 | 83 | 50 | 50 |  |
  > 4 | 18 | 8.5 | 72 | 22 | 0 | 0.04 |
Pre-chemoradiotherapy serum CA19-9 level (U/ml) | ||||||
  ≤ 1,000 | 29 | 10.8 | 90 | 47 | 42 |  |
  > 1,000 | 11 | 6.4 | 54 | 9 | 0 | 0.002 |
Local progression before starting chemoradiotherapy | ||||||
  Absent | 4 | NA | 80 | 60 | 60 |  |
  Present | 26 | 8.8 | 76 | 28 | 19 | 0.15 |
Time from the start of primary chemotherapy to chemoradiotherapy | Â | |||||
  ≤ 6 months | 12 | 8.5 | 75 | 33 | 25 |  |
  > 6 months | 18 | 8.8 | 78 | 33 | 28 | 0.9 |
Combined chemoradiotherapy agents | ||||||
 5-FU | 14 | 7.2 | 64 | 21 | 14 |  |
 S-1 | 16 | 9.9 | 88 | 44 | 37 | 0.09 |